AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04678869
Drug: Ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: prophylactic ciprofloxacin (10mg/kg BD, enteral/IV)
Trial: NCT04678869
Drug: Antibiotic
RxNorm normalized name: Antibiotics
DrugBank: Gramicidin D (DB00027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care antibiotic as per local policy
Trial: NCT05165875
Drug: Hydrocortisone-Lidocaine
RxNorm normalized name: Hydrocortisone-Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention will be done on the same day based on the randomization.~For the steroid injection group, a 1ml injection of a mixture of 0.5ml triamcinolone acetonide (50mg/5ml) and 0.5ml 1% lignoacaine is given intra-thecally into the first extensor compartment.~For both groups, routine analgesia is not prescribed but the use is not restricted to the participants.
Trial: NCT05654454
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC 6
Trial: NCT05133349
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib 12mg capsules given orally on once daily in 21-day cycle until disease progression or treatment intolerance(14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21), the dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.
Trial: NCT04625699
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4 doses of Durvalumab 1500 mg IV Day 1, q28 days (For example, interventions involving drugs may include dosage form, dosage, frequency, and duration.)
Trial: NCT04625699
Drug: Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of Tremelimumab 300 mg IV Day 1, q56 days
Trial: NCT06238024
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single dose intravenous application
Trial: NCT06238024
Drug: NaCl 0.9% 100ml
RxNorm normalized name: MORPHINE 1MG/ML NACL 0.9% 100ML
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose intravenous application
Trial: NCT06525714
Drug: cisplatin oxaliplatin tegafur
RxNorm normalized name: tegafur
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Within 48 hours postoperative, the first infusion was performed with 3000-4000 ml of saline and 50 mg/m2 cisplatin at 43°C, with an infusion rate of 600 ml/min for a duration of 2 hours. During treatment, close attention is given to the patient's heart rate, blood pressure, oxygenation, and other vital signs. A total of 2 HIPEC treatments were conducted, each 48 hours apart. Systemic chemotherapy is initiated 3-4 weeks postoperative for 6-8 cycles using SOX: intravenous injection of oxaliplatin (130 mg/m2) on the first day and oral administration of tegafur (40-60 mg twice daily, with doses adjusted for body surface area: \<1.25 m2, 40 mg; 1.25m2 ≤ body surface area ≤ 1.5m2, 50mg; body surface area \>1.5m2, 60 mg bid) from day 1 to 14.
Trial: NCT06380205
Drug: Povorcitinib
RxNorm normalized name: Povorcitinib
DrugBank: Povorcitinib (DB18855)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Povorcitinib will be administered at protocol defined dose.
Trial: NCT05707390
Drug: Mezigdomide
RxNorm normalized name: Mezigdomide
DrugBank: Mezigdomide (DB17584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT04912141
Drug: conestat alfa or placebo
RxNorm normalized name: conestat alfa
DrugBank: Conestat alfa (DB09228)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Conestat alfa will be dosed by body weight at 50 U/kg (maximum 4200 U) or 100 U/kg (maximum 8400 U).~Placebo will consist of normal saline (NaCl 0.9%). The interventions will be given to the patients by IV-line.
Trial: NCT04727528
Drug: Sodium zirconium cyclosilicate
RxNorm normalized name: sodium zirconium cyclosilicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Investigational medicinal product
Trial: NCT04418414
Drug: Gene therapy
RxNorm normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD34+ hematopoietic stem cells transduced with CD68-ET3 lentiviral vector (encoding human factor VIII gene) is administered by IV infusion following conditioning regimen with busulfan and anti-thymocyte globulin.
Trial: NCT05253794
Drug: Colchicine 0.6 mg
RxNorm normalized name: colchicine 0.6 MG
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral tablet daily for 6 months
Trial: NCT05308030
Drug: Rivaroxaban and Aspirin
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: After the endovascular intervention, Anticoagulant therapy plus Antiplatelet therapy will be maintained (Aspirin 100 mg once daily and Rivaroxaban 2.5 mg twice daily) for 3 months, and then Aspirin alone indefinitely
Trial: NCT06233799
Drug: extended-release naltrexone (XR-NTX)
RxNorm normalized name: bupropion / naltrexone Extended Release Oral Tablet
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once per three weeks injections of extended-release naltrexone
Trial: NCT06233799
Drug: extended release bupropion (BUP-XL) tablets (BUP-XL)
RxNorm normalized name: bupropion Extended Release Oral Tablet
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily oral extended release bupropion tablets
Trial: NCT06491355
Drug: mfolfox6 and hlx04 regimen and Serplulimab
RxNorm normalized name: Anacin Aspirin Regimen
DrugBank: Serplulimab (DB17451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mfolfox6 and hlx04 regimen induction therapy followed by combined treatment with slulimumab in the experimental arm. In the active comparator. only with mfolfox6 and hlx04 regimen treatment.
Trial: NCT05963347
Drug: Golidocitinib
RxNorm normalized name: Golidocitinib
DrugBank: Golidocitinib (DB18057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose. Starting dose of golidocitinib is 75 mg QD. If tolerated, subsequent cohorts will test ascending doses of golidocitinib.
Trial: NCT06703229
Drug: The Transversus Abdominis Plane (TAP) block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: or injectate preparation, utilizing ultrasound guidance while the patient was supine. In the D1 group, patients were administered 20 mL of 0.25% isobaric bupivacaine with 0.5 mcg/kg of dexmedetomidine.
Trial: NCT06703229
Drug: The transverse abdominis plane (TAP) block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in the D2 group received 20 mL of 0.25% isobaric bupivacaine with 1 mcg/kg of dexmedetomidine.
Trial: NCT06688799
Drug: CD19 CAR-T cells
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
Trial: NCT00407017
Drug: Gatifloxacin
RxNorm normalized name: Gatifloxacin
DrugBank: Gatifloxacin (DB01044)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00407017
Drug: Pred Forte
RxNorm normalized name: Pred Forte
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00407017
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05382546
Drug: Ketorolac Tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac tromethamine, alcohol free formulation, 1.0 mg/mL in saline solution (\~0.9% NaCl) adjusted to a pH of \~7.4. Contained in a sterile, polyolefin bag filled with 125 mL of NTM-001.
Trial: NCT05655273
Drug: Prograf
RxNorm normalized name: Prograf
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants randomized to the Prograf (control) arm will continue with their current twice daily dosing of Prograf.
Trial: NCT05655273
Drug: Envarsus
RxNorm normalized name: Envarsus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants randomized to Envarsus arm will have their current daily dose of Prograf converted to once-daily Envarsus dose according to the following ratio: 0.7 x the current daily Prograf dose. Envarsus is available in 3 dose strengths- 0.75mg, 1.0mg, and 4.0mg. The actual dose of Envarsus will be rounded to an amount that can be administered using the above tablet strengths.
Trial: NCT06398158
Drug: Ravulizumab
RxNorm normalized name: ravulizumab
DrugBank: Ravulizumab (DB11580)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All study participants will receive commercially covered ravulizumab consistent with the indication, dose and frequency contained within the approved label.
Trial: NCT05055726
Drug: Benzydamine Hydrochloride 0.15% w/v oromucosal solution
DrugBank: Benzydamine (DB09084)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzydamine Hydrochloride 0.15% w/v oromucosal solution (mouthwash), Angelini Pharma S.p.A.
Trial: NCT06405178
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin Sensitizer
Trial: NCT06405178
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sodium-Glucose Co-transporter-2
Trial: NCT06405178
Drug: Dapagliflozin/Metformin
RxNorm normalized name: DAPAGLIFLOZIN/METFORMIN
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anti diabetic drug
Trial: NCT06405178
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aromataze inhibitor
Trial: NCT04681430
Drug: Camostat Mesilate
RxNorm normalized name: Camostat mesilate
DrugBank: Camostat (DB13729)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets over 7 days, daily dose of 600 mg split into 3 doses
Trial: NCT04681430
Drug: Placebo for Camostat Mesilate
DrugBank: Camostat (DB13729)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Tablets over 7 days, split into 3 doses
Trial: NCT05340335
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A beginning dose of remimazolam is 1mg/kg/hr. When sedation is not achieved in 10 minutes, the dose will be increased by 0.1mg/kg/hr in the next patient. When sedation is successful, the same dose will be used with the probability of 0.89, or the dose will be decreased by 0.1mg/kg/hr with the probability of 0.11 in the next patient. (maximal dose: 2mg/kg/hr)
Trial: NCT05057689
Drug: Intranasal Dexmedetomidine (4 mcg/kg)
RxNorm normalized name: dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine 100 mcg/mL (concentration of 200 mcg/2 mL) will be atomized for intranasal administration at a dose of 4 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart prior to laceration repair. The maximum dose will be 200 mcg.
Trial: NCT05057689
Drug: Intranasal Midazolam (5 mg/kg)
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam 5 mg/mL (concentration of 10 mg/2 mL) will be atomized for intranasal administration at a dose of 0.3 mg/kg (0.06 mL/kg) according to a weight-based dosing chart prior to laceration repair. The maximum dose will be 10 mg.
Trial: NCT05417776
Drug: Dotarem
RxNorm normalized name: Dotarem
DrugBank: Gadoteric acid (DB09132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dotarem will be administered during MRI portion of study.
Trial: NCT05720559
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin via intravenous drip on d1 at a dose of 130mg/m2 × patient 's body surface area
Trial: NCT05720559
Drug: S1
RxNorm normalized name: LS11
DrugBank: LS11 (DB05918)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally on d2-d15 at 20 mg three times daily
Trial: NCT05720559
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab combined with chemotherapy was administered simultaneously, once every three weeks,and intravenous drip was performed before oxaliplatin at a dose of 250 mg/m2 × body surface area.
Trial: NCT05720559
Drug: Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole 0.4g/time, qd
Trial: NCT05720559
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A 25,000 units/time, qd
Trial: NCT05161221
Drug: OxyCODONE 5 mg Oral Tablet
RxNorm normalized name: oxyCODONE 5 mg oral tablet
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive 20 OxyCODONE 5 mg Oral Tablet post surgery for pain control
Trial: NCT05919550
Drug: search for a clozapine intake
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: search for a clozapine intake
Trial: NCT06382129
Drug: BL-B01D1
RxNorm normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Trial: NCT05161221
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive pre-operative adductor canal block with liposomal bupivacaine (Exparel)
Trial: NCT06382129
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Trial: NCT04771754
Drug: Dolutegravir
RxNorm normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg once daily orally
Trial: NCT05113745
Drug: AXS-12 (reboxetine)
RxNorm normalized name: AX
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AXS-12 tablets, taken twice daily
Trial: NCT05125042
Drug: Amiodarone hydrochloride tablet
RxNorm normalized name: Amiodarone Hydrochloride Tablets
DrugBank: Amiodarone (DB01118)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with persistent AF after undergoing catheter ablation only take amiodarone hydrochloride tablets 200mg bid, 1 month; 200mg qd,maintained to 3 months.All patients, who had no signs of recurrence three months after surgery, stopped taking medication.
Trial: NCT00351221
Drug: rhIGF-1/rhIGFBP-3
DrugBank: rhIGFBP-3 (DB05897)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05227118
Drug: MK-8189
RxNorm normalized name: MK-8189
DrugBank: MK-8189 (DB19153)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8189 administered orally once a day (QD) at a titration via tablet in 4 mg and 12 mg dose strengths
Trial: NCT05859711
Drug: thyme honey mouth rinse
RxNorm normalized name: THYME
DrugBank: Thyme (DB10983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral rinses (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day starting in the 4th week of radiotherapy and for one month after completion of radiotherapy. (Charalambous et al.,2017)
Trial: NCT00228839
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT06523049
Drug: Vorolanib Tablets
RxNorm normalized name: Vorolanib
DrugBank: Vorolanib (DB15247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-targeted receptor tyrosine kinase inhibitor with potent inhibition of VEGFR2, KIT, PDGFR, FLT3 and RET, exerting anti-tumor effects mainly through inhibition of neovascularization.
Trial: NCT06523049
Drug: Sintilimab Injection
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant human-derived immunoglobulin G (IgG4)-type anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, by binding to PD-1 and blocking PD-1 binding to PD-L1 and PD-L2, disarms the immunosuppressive effect, activates T-cell function, and enhances T-cell immunosurveillance and killing ability against tumors to generate tumor immune response.
Trial: NCT03997097
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients randomised in the group 1 will receive sildenafil in 3 oral doses of 20 mg per day
Trial: NCT00000962
Drug: Nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06381180
Drug: Tetrahydrocannabinol
RxNorm normalized name: Tetrahydrocannabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plant cannabis that will be vaporized
Trial: NCT06381180
Drug: Cannabidiol
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Plant cannabidiol that will be vaporized
Trial: NCT06072118
Drug: Adrenomedullin
RxNorm normalized name: Adrenomedullin
DrugBank: Adrenomedullin (DB19102)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing at 15 ng/kg/min for 8 hours is continued for 14 days.
Trial: NCT04749095
Drug: Erector spinae plane block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bilateral ESP block will be injected with 20 ml of 0.25% bupivacaine
Trial: NCT04749095
Drug: sham subcutaneous infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bilateral ESP block will be injected with 20 ml of normal saline
Trial: NCT06158035
Drug: Phenylephrine
RxNorm normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An initial infusion dose of prophylactic phenylephrine (75 ug) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 12.5 ug of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
Trial: NCT06109415
Drug: Bupivacaine Hydrochloride
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg
Trial: NCT06201039
Drug: 0.5% Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prior to the end of neck dissection and any additional procedures, the bilateral catheter will be placed adjacent to the cervical plexus underneath the internal jugular vein, left in place for 24 hours and removed in a similar way to the Redon drainage by the surgeon. The CWI block will start immediately at a speed of 4ml/h containing 0.5% lidocaine hydrochloride + 1:400000 adrenaline.
Trial: NCT06447701
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single dose intravenous application
Trial: NCT06447701
Drug: NaCl 0.9% 100ml
RxNorm normalized name: MORPHINE 1MG/ML NACL 0.9% 100ML
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose intravenous application
Trial: NCT04039204
Drug: Elagolix
RxNorm normalized name: ELAGOLIX
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This orally active, reversible GnRH antagonist will be used to suppress endometriosis by lowering estrogen levels for 2 months prior to FET
Trial: NCT04039204
Drug: Ortho Cyclen
RxNorm normalized name: Ortho Cyclen
DrugBank: Norgestimate (DB00957)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral contraceptive prescribed by physician.
Trial: NCT05394285
Drug: Hetrombopag
RxNorm normalized name: Hetrombopag
DrugBank: Hetrombopag (DB16184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first chemotherapy cycle (single center, open label, randomized controlled):~When platelets were \<50\*109/L, oral hetrombopag 7.5 mg/day was started. When the platelet count is \>100\*109/L, the administration is suspended.~2nd chemotherapy cycle (exploratory study): Prophylactic use (60 cases in the test group and the control group): oral hetrombopag 7.5 mg/day (initial dose) was started on d2 after chemotherapy for 14 days.
Trial: NCT05394285
Drug: rh-TPO
RxNorm normalized name: Tpoxx
DrugBank: Recombinant Human Thrombopoietin (DB16364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first chemotherapy cycle (single center, open label, randomized controlled):~Start using rh-TPO 15000 units/day (subcutaneous injection) when platelets are less than 50\*109/L. When the platelet count is more than 100\*109/L, the administration is suspended.~2nd chemotherapy cycle (exploratory study): Prophylactic use (60 cases in the test group and the control group): oral hetrombopag 7.5 mg/day (initial dose) was started on d2 after chemotherapy for 14 days.
Trial: NCT04970121
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Duloxetine, tablets, 20mg as starting dose and up to 60mg as maximum dose, once daily.~Taxanes is used according to manual instruction and patient condition.
Trial: NCT04608331
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours. The pump is established with morphine (0.5 mg/ml) and dexmedetomidine (1.25 microgram/ml), in a total volume of 160 ml normal saline, and programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate of 1 ml/h.